Please assess the completion status of the following clinical trial:

Trial Title: GIP Receptor Antagonist Studies in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normal kidney function, liver function and hemoglobin levels.~Exclusion Criteria:~* Medication, Diabetes type 1 or 2, BMI \> 25, first degree relatives with Type 2 Diabetes

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of saline
- GIP(1-42) (Type: ACTIVE_COMPARATOR): Infusion of agonist, GIP(1-42)
- GIP-A (Type: EXPERIMENTAL): Infusion of GIP-A alone
- GIP-A + GIP(1-42) (Type: EXPERIMENTAL): Infusion of GIP-A and GIP(1-42)

Based on this trial design, predict the completion outcome and termination type (if applicable).